Risk of perinatal mortality associated with inhaled corticosteroid use for the treatment of asthma during pregnancy - 07/08/11
Reprint requests: Lucie Blais, PhD, Université de Montréal, Faculté de pharmacie, C.P. 6128, Succursale Centre-ville, Montréal, Québec H3C 3J7, Canada.Abstract |
Background |
Four studies investigating the association between inhaled corticosteroid (ICS) use during pregnancy and perinatal mortality reported no significantly increased risk. These studies must be interpreted with caution because they have insufficient statistical power and a lack of adjustment for potential confounders.
Objectives |
We sought to evaluate whether asthmatic women exposed to ICSs during pregnancy are more at risk of perinatal mortality than asthmatic women not exposed. We also sought to estimate the risk of perinatal mortality as a function of the daily ICS dose taken during pregnancy.
Methods |
From the linkage of 3 administrative databases from Quebec, a cohort including 13,004 single pregnancies from asthmatic women was constructed. We used a 2-stage sampling cohort design to obtain information on cigarette smoking from the medical charts of 487 mothers. The final estimates of the odds ratios (ORs) of perinatal mortality were estimated with a logistic regression model.
Results |
The cohort was formed of 4,140 women who used greater than 0 to 250 μg/d ICS, 1,140 women who used greater than 250 μg/d ICS, and 7,724 nonusers of ICSs during pregnancy. Women exposed to ICSs (any dose) had a nonsignificant increased risk of perinatal mortality (OR, 1.07; 95% CI, 0.70-1.61). The use of greater than 250 μg/d ICS was associated with a nonsignificant 52% increased risk of perinatal mortality (OR, 1.52; 95% CI, 0.62-3.76).
Conclusion |
The risk of perinatal mortality was not found to be significantly associated with ICS use during pregnancy. The result associated with higher doses of ICSs is limited due to a lack of statistical power and a possibility of residual confounding by asthma severity and control.
El texto completo de este artículo está disponible en PDF.Key words : Asthma, pregnancy, perinatal mortality, inhaled corticosteroids
Abbreviations used : ED, GEE, ICS, ISQ, MED-ECHO, OR, RAMQ, RR
Esquema
| Supported by grants from the Fonds de la recherche en santé du Québec (FRSQ) and the Canadian Institute for Health Research (CIHR). |
|
| Disclosure of potential conflict of interest: M.-F. Beauchesne has received remuneration for lessons from GlaxoSmithKline and AstraZeneca. C. Lemière has received research support from the National Institute for Occupational Safety and Health and GlaxoSmithKline. E. Rey is a speaker for Leo Pharma. The rest of the authors have declared that they have no conflict of interest. |
Vol 126 - N° 4
P. 772 - octobre 2010 Regresar al número
Artículo precedente
- The immunostimulant OM-85 BV prevents wheezing attacks in preschool children
- Cem Hasan Razi, Koray Harmancı, Ayhan Abacı, Osman Özdemir, Şamil Hızlı, Rahime Renda, Fersin Keskin
- Alveolar nitric oxide concentration, small airways inflammation, and targeted asthma therapy: Are we there yet?
- H. William Kelly
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?